{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-021064","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.548238+00:00","generated_at":"2026-05-16T08:26:41.446892+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock","bullets":["Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.","Exchanged 22 Series L preferred shares (Iliad) and 99.38 shares (Streeterville) for 0.72M and 3.25M pre-funded warrants.","Exchanged 87.78 Series M shares (Iliad) and 69.44 shares (Streeterville) for 2.87M and 2.27M pre-funded warrants.","Warrants exercisable immediately at $0.001/share; no cash received in the exchanges."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-021064","json":"https://secwatch.observer/filing/0001193125-26-021064.json","markdown":"https://secwatch.observer/filing/0001193125-26-021064.md","text":"https://secwatch.observer/filing/0001193125-26-021064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/jagx-20260116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:26:41.446892+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16ce3f325226a2243ed60b779f45b51fb9c10ca3","claim":"Jaguar Health, Inc. entered into Streeterville Royalty Interest Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Streeterville Royalty Interest Exchange Agreement”) with Streeterville.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 1,111,837 shares of Common Stock in ex"},{"label":"Effective","value":"2026-01-16"}]},{"claim_id":"17b18c86cbe606d12907353c677cde89b5333c89","claim":"Jaguar Health, Inc. entered into Streeterville Series L Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock (the “Fourth Pre-Funded Warrant”) to Streeterville in exchange for 99.3822 shares of Series L Preferred Stock held by Streeterville.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 3,249,908 shares of Common Stock in ex"},{"label":"Effective","value":"2026-01-16"}]},{"claim_id":"20105aacb21671271f2867d7722d9b35d66ac593","claim":"Jaguar Health, Inc. entered into Streeterville Series M Exchange Agreement with Streeterville Capital, LLC valued at Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “Streeterville Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock (the “Sixth Pre-Funded Warrant”) to Streeterville in exchange for 69.44 shares of Series M Preferred Stock held by Streeterville.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 2,270,765 shares of Common Stock in ex"},{"label":"Effective","value":"2026-01-16"}]},{"claim_id":"45b8a54bf33381667798e7bd535e09832f27de1b","claim":"Jaguar Health, Inc. entered into Iliad Series M Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series M Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock (the “Fifth Pre-Funded Warrant”) to Iliad in exchange for 87.78 shares of Series M Preferred Stock held by Iliad.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Iliad Research and Trading, L.P."},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 2,870,503 shares of Common Stock in ex"},{"label":"Effective","value":"2026-01-16"}]},{"claim_id":"abd59641e08e580c44337044a60d2a13dca4800d","claim":"Jaguar Health, Inc. entered into Iliad Royalty Interest Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement (the “Iliad Royalty Interest Exchange Agreement”) with Iliad.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Iliad Research and Trading, L.P."},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 1,553,844 shares of Common Stock in ex"},{"label":"Effective","value":"2026-01-16"}]},{"claim_id":"b001bd708dba4eeeb6a1cc780c03890c101cc3dd","claim":"Jaguar Health, Inc. entered into Iliad Series L Exchange Agreement with Iliad Research and Trading, L.P. valued at Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch (effective 2026-01-16).","evidence_excerpt":"On January 16, 2026, the Company entered into a privately negotiated exchange agreement with Iliad (the “Iliad Series L Exchange Agreement”), pursuant to which the Company issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock (the “Third Pre-Funded Warrant”) to Iliad in exchange for 22 shares of Series L Preferred Stock held by Iliad.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526021064/0001193125-26-021064-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Iliad Research and Trading, L.P."},{"label":"Value","value":"Issued a pre-funded common stock purchase warrant to purchase 719,424 shares of Common Stock in exch"},{"label":"Effective","value":"2026-01-16"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}